Transform how you analyse drug development risk
With the only transparent analysis of drug development risk at the product level.
Only one near-term event remains to determine whether Keytruda will face any kind of challenge in first-line NSCLC.
2018 started with the promise of a first-line lung cancer shakeout but it looks likely to end with Merck & Co’s Keytruda even more entrenched than before.
This report into the first-line NSCLC space discusses key upcoming trial readouts and regulatory decisions. Vantage puts into context the developments that over recent months have seen Keytruda consolidate its dominant position.